Posted on

Aerpio Pharmaceuticals, Inc. is a growing biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio’s two lead programs include a Tie2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1a (HIF1a) stabilizer for wound healing and the treatment of inflammatory bowel disease. Aerpio is a spin-out from Akebia Therapeutics.